6-((5-Cyanopyridin-2-yl)amino)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-methylnicotinamide

ID: ALA4469750

Chembl Id: CHEMBL4469750

PubChem CID: 75201786

Max Phase: Preclinical

Molecular Formula: C23H21N9O2

Molecular Weight: 455.48

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  CNC(=O)c1cnc(Nc2ccc(C#N)cn2)cc1Nc1cccc(-c2ncn(C)n2)c1OC

Standard InChI:  InChI=1S/C23H21N9O2/c1-25-23(33)16-12-27-20(30-19-8-7-14(10-24)11-26-19)9-18(16)29-17-6-4-5-15(21(17)34-3)22-28-13-32(2)31-22/h4-9,11-13H,1-3H3,(H,25,33)(H2,26,27,29,30)

Standard InChI Key:  IIRJKMJZLJRGQN-UHFFFAOYSA-N

Associated Targets(Human)

JAK1 Tclin JAK1/TYK2 (259 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TYK2 Tclin Tyrosine-protein kinase TYK2 (5029 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Tyk2 Non-receptor tyrosine-protein kinase TYK2 (29 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 455.48Molecular Weight (Monoisotopic): 455.1818AlogP: 3.00#Rotatable Bonds: 7
Polar Surface Area: 142.67Molecular Species: NEUTRALHBA: 10HBD: 3
#RO5 Violations: HBA (Lipinski): 11HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 11.01CX Basic pKa: 6.71CX LogP: 3.35CX LogD: 3.34
Aromatic Rings: 4Heavy Atoms: 34QED Weighted: 0.38Np Likeness Score: -1.33

References

1. Wrobleski ST, Moslin R, Lin S, Zhang Y, Spergel S, Kempson J, Tokarski JS, Strnad J, Zupa-Fernandez A, Cheng L, Shuster D, Gillooly K, Yang X, Heimrich E, McIntyre KW, Chaudhry C, Khan J, Ruzanov M, Tredup J, Mulligan D, Xie D, Sun H, Huang C, D'Arienzo C, Aranibar N, Chiney M, Chimalakonda A, Pitts WJ, Lombardo L, Carter PH, Burke JR, Weinstein DS..  (2019)  Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.,  62  (20): [PMID:31318208] [10.1021/acs.jmedchem.9b00444]

Source